Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. · 2022

Read Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. by Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9205778.txt.

Introduction

Qi and co-authors report interim results of a phase 1 trial of Claudin18.2-specific CAR T cells in digestive cancers. CAR T therapy works well in blood cancers but poorly in solid tumors. Claudin18.2 is common in gastric and other digestive cancers, which makes it a target. The trial treated patients whose cancers had already had other therapy.

In all, 37 patients got one of three cell doses. All had grade 3 or higher blood toxicity, and most had mild cytokine release syndrome. No severe syndrome, nerve toxicity, or treatment deaths occurred. The overall response rate reached 48.6%, and disease control was high across the group. Response in gastric cancer was higher still. The authors call the early results promising for heavily treated patients.

Catalog record

CREATORQi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9205778

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results By Changsong Qi, Jifang Gong, Jian Li, Dan Liu, Yanru Qin, Sai Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yanshuo Cao, Xiaotian Zhang, Zhihao Lu Published in: Nature Medicine DOI: 10.1038/s41591-022-01800-8 ABSTRACT Abstract Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the interim analysis results of an ongoing, open-label, single-arm, phase 1 clinical trial of CLDN18.2-targeted CAR T cells (CT041) in patients with previously treated, CLDN18.2-positive digestive system cancers (NCT03874897). The primary objective was safety after CT041 infusion; secondary objectives included CT041 efficacy, pharmacokinetics and immunogenicity. We treated 37 patients with one of three CT041 doses: 2.5 × 108, 3.75 × 108 or 5.0 × 108 cells. All patients experienced a grade 3 or higher hematologic toxicity. Grade 1 or 2 cytokine release syndrome (CRS) occurred in 94.6% of patients. No grade 3 or higher CRS or neurotoxicities, treatment-related deaths or dose-limiting toxicities were reported. The overall response rate (ORR) and disease control rate (DCR) reached 48.6% and 73.0%, respectively. The 6-month duration of response rate was 44.8%. In patients with GC, the ORR and DCR reached 57.1% and 75.0%, respectively, and the 6-month overall survival rate was 81.2%. These initial results suggest that CT041 has promising efficacy with an acceptable safety profile in patients with heavily pretreated, CLDN18.2-positive digestive system cancers, particularly in those with GC. Subject terms: Cancer immunotherapy, Gastric cancer, Gastrointestinal cancer, T cells, Phase I trials MAIN Although CAR T cell therapy has displayed remarkable clinical efficacy in various types of hematologic malignancies1–4, its efficacy in solid tumors is still very limited5–7. CLDN18.2 is the gastric-specific isoform of the tight junction protein of CLDN18. It is highly expressed in multiple cancers, especially in cancers of the digestive system, making it a potential target for anti-tumor therapy8,9. The monoclonal antibody zolbetuximab is the first CLDN18.2-targeted treatment under clinical development. As a monotherapy, zolbetuximab reported an ORR of 9% in CLDN18.2-positive patients with recurrent or refractory advanced gastric cancer/gastroesophageal junction (GC/GEJ) cancer who had received at least one prior line of therapy10. Zolbetuximab combined with epirubicin, oxaliplatin and capecitabine (EOX) achieved an ORR of 39.0% versus 25.0% (P = 0.034), and a duration of response (DOR) of 32.6 weeks versus 21.7 weeks (P = 0.023) when compared to EOX alone in CLDN18.2-positive patients with advanced GC/GEJ cancer in the first-line setting11. As the mechanism of action between monoclonal antibodies and CAR T cells is known to be quite different, it is necessary to explore the anti-tumor activities of CLDN18.2 CAR-T in gastrointestinal (GI) cancer. CT041 contains genetically engineered autologous T cells that express the CLDN18.2-targeted CAR. The CAR structure consists of a humanized anti-CLDN18.2 single-chain variable fragment, a CD8α hinge region, a CD28 co-stimulatory domain and a CD3ζ signaling domain (Supplementary Fig. 1). Our previous preclinical data indicated that CT041 had antigen-specific anti-tumor effects on GC, leading to significant tumor regression without weight loss in immunodeficient mice12. GC has a poor prognosis with limited treatment options, including first-line monotherapies or combinations of oxaliplatin, fluoropyrimidine, irinotecan, paclitaxel, anti-PD-1 antibody, docetaxel and carboplatin with or without trastuzumab depending on HER2 expression status, as well as ramucirumab (VEGFR-2 monoclonal antibody) plus paclitaxel as second-line treatment13. Similarly, limited treatments exist for metastatic pancreatic cancer (PC), including gemcitabine with or without nab-paclitaxel, FOLFIRINOX and nanoliposomal irinotecan with fluorouracil14. A previous single-center clinical trial (NCT03159819) indicated that CT041 was well-tolerated and could be a promising therapy for patients with gastric and pancreatic cancers15. Therefore, we initiated an open-label, multicenter, single-arm, dose-escalation/de-escalation and dose-expansion phase 1 trial to investigate the safety, efficacy, pharmacokinetics and immunogenicity of CT041 in patients with cancers of the digestive system (Extended Data Fig. 1). Here we report the outcomes from a non-prespecified interim analysis of this ongoing trial (NCT03874897). [Figure: Study flow diagram and procedure schema.a, Two-phase study design: a dose escalation/de-escalation phase and a dose-expansion phase to determine the recommended phase II dose (RP2D). b, Schema of study procedure. DLT, dose-limiting toxicity; ECOG, Eastern Cooperative Oncology Group performance status.] RESULTS Study design and baseline characteristics of patients The trial recruited adult patients with advanced digestive system cancers whose tumor tissues expressed CLDN18.2 as confirmed by immunohistochemistry (IHC), who had Eastern Cooperative Oncology Group (ECOG) performance status scores of 0 or 1 and who had been treated with at least one line of standard systemic therapy. Patients were excluded from the study if they had a target lesion larger than 4 cm at the time of apheresis; active infection including, but not limited to, hepatitis B virus (HBV), hepatitis C virus (HCV) and tuberculosis; brain metastases; unstable or active gastric ulcer or gastroenterological bleeding; central or widespread metastatic lung lesion(s); or massive liver metastases. A complete list of eligibility criteria can be found in the Methods. The trial consists of a modified ‘3 + 3’ pattern dose-escalation/de-escalation phase and a dose-expansion phase. In the dose-escalation/de-escalation phase, patients with CLDN18.2-positive tumors received one of three CT041 dose levels: 2.5 × 108, 3.75 × 108 or 5.0 × 108 cells. Based on discussions with the Data Safety Monitoring Committee (DSMC), the 2.5 ×108 CAR T cell dose was recommended for the dose-expansion phase (Extended Data Fig. 1). From 26 March 2019 through 8 April 2021, 74 participants signed informed consent; 59 patients were apheresed; and 49 patients were infused. The first 37 patients were included in this interim analysis, including 28 with GC/GEJ cancer, five with PC and four with other digestive system tumor types (Table 1 and Extended Data Table 1). These patients received CT041 infusion and had completed at least 12 weeks of safety, efficacy and pharmacokinetics assessments after the first infusion (Table 1, Extended Data Table 1 and Extended Data Fig. 2). The median age was 53.0 (25–74) years, and 64.9% (24/37) of patients were men. All enrolled patients were diagnosed with metastatic disease, and 50% of them had at least three organ sites involved. Among the 28 patients with GC/GEJ cancer, 25 (89.3%) had received at least two lines of therapy or at least a triple combination of fluoropyrimidine, oxaliplatin and paclitaxel, and 12 (42.9%) had received prior anti-PD-1/PD-L1 antibody therapy. No HER2-positive patients were enrolled in this study. The cell doses of 2.5 × 108, 3.75 × 108 and 5.0 × 108 were administered to 28, six and three patients, respectively, with a median follow-up of 8.5 months (range, 2.9–19.4 months) (Supplementary Table 1) since apheresis. As of the data cutoff date (8 April 2021) for this interim analysis, patient enrollment continues for the study, and the results will be reported when available. [Table: Baseline characteristics of all patients and patients with GC who received CT041] [Table: Patient level baseline, treatment and response characteristics (modified intention-to-treat analysis set)] [Figure: CONSORT Diagram.GC/GEJ, gastric/gastroesophageal junction cancer; PC, pancreatic cancer. * Data are from the first 37 patients who were treated with CT041 and completed at least 12 weeks of follow-up as of the data cutoff date, 08 April 2021.] A total of 28 (75.7%) patients

Read the complete text